We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.00 | 1.13% | 267.50 | 265.00 | 267.00 | 273.00 | 265.50 | 266.50 | 18,840 | 16:35:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
23/8/2021 02:28 | Being received quite well in HK at present (+3.5%): Hong Kong, Shanghai & Florham Park, NJ — Monday, August 23, 2021: HUTCHMED (China) Limited (“HUTCHMED&rdq | lauders | |
20/8/2021 10:14 | Yup. I've got a small stake in Tencent as well 😕. | nahoon | |
20/8/2021 08:51 | The likes of Alibaba have halved in the year and are now back to levels not seen since Aug 2019.There is little sign of the Chinese authorities loosening their administrative grip in the field of retail,tech and finance.Some fund managers regard the fall in the Chinese exchanges as a buying opportunity but others have sold out not being prepared to guess the likely machinations of the Chinese political masters.Long term its probably right to maintain a Chinese weighting in a global portfolio but its very irritating to see the slump in stock prices purely due to political interference whether that interference is justified or not.I feel that the fall back in HCM is almost entirely due to shifts of global capital out of Chinese exchanges and its difficult to see confidence returning soon.There's a health warning attached to buying all chinese related securities just now. | steeplejack | |
20/8/2021 07:41 | I'm guessing it's just caught up in the worries over the Chinese government's crackdown on listed companies. But on the upside, this is from today's FT: "BlackRock’s research unit has said China should no longer be considered an emerging market and recommended investors boost their exposure to the country by as much as three times." Patience... | nahoon | |
20/8/2021 07:37 | Morning All8.8% drop this am in HK. Has anyone got insight, is it profit taking after recent launch, worries over tension between Ch and USA, non shares news? I had a look over the usuals and nothing to be seen. | chester9 | |
14/8/2021 03:57 | Two links courtesy of "tacly" over on the LSE BB: Hutchmed (HCM US) Building momentum towards a fully-fledged biopharma ■ Hutchmed (HCM) is a China-based biopharma company with an proven in-house innovative pipeline focusing on oncology ■ HCM extends its global commercial footprint, paving the way for internal pipeline monetization and external BD opportunities ■ We initiated coverage on HCM with a BUY rating and FY22E SOTP-based TP of USD54.6, implying 28% upside potential + We know the future is bright. These two help reinforce that viewpoint. | lauders | |
11/8/2021 06:27 | Trinity Delta have issued a new brief update note:- | nerdofsteel | |
10/8/2021 16:52 | Evaluate's World Preview 2021 Outlook to 2026 has been published today and there's a specific section on China (P10) | nerdofsteel | |
10/8/2021 09:08 | Getting some nice coverage in the trade press on the Epizyme deal | nerdofsteel | |
10/8/2021 08:01 | And sense a break of 650p is getting closer and closer. After many years price momentum seems to be building. | its the oxman | |
10/8/2021 06:07 | HUTCHMED is uniquely positioned to make the most of TAZVERIK® Summary rationale *ES = epithelioid sarcoma, a solid tumor; FL = follicular lymphoma, a hematological malignancy –a subtype of non-Hodgkin’s lymphoma. Global First-in-Class Product First and only US FDA approved EZH2 inhibitor 1stapprovals in Jan & Jun 2020, for ES & FL* Accelerates China Hematology Commercialization Advances build-out of hematology sales team–ahead of potential launches of 5 clinical assets Manufacturing expertise & capabilities–s Pipeline Synergy Broad PotentialApplicabili Inhibit epigenetics inhibit cell proliferation– Highly favorable safety profile–potent This is a very good stategic play for Hutchmed. We have to hope Epizyme's viability continues, which it should as U.S. sales really start to take off this year. | nerdofsteel | |
09/8/2021 14:35 | NofS - Have you changed your name here to yidarmyTom? LSE postings would tend to support this conclusion. Good meeting just completed. Looks like this is a specific product that HCM are interested in and for now the net is not being cast for more like it just now. Opportunity and the great safety profile of TAZVERIK® made it a worthy candidate. Look forward to more developments as they come. | lauders | |
09/8/2021 09:58 | I think today's deal on TAZVERIK® gives Hutchmed a great opportunity top leverage its sales teams and other infrastructure in China to market drugs owned by Companies who want to partner and who have no resoyrce in region, or cannot navigate the Chinese Regulatory system. Beigene have made a great success of it. TAZVERIK® is forecast to exceed $900m pa peak sales in the U.S. so it could approach that in what is a larger chinese market, even with NRDL discounts. I'm looking forward to the Company's view on forecast peak sales on the conference call today. I can seem more of these licencing deals coming our way. I also look froward to increased revenue forecasts from Analysts. | yidarmytom | |
09/8/2021 07:53 | Shares up a tad so guess it's perceived as a positive. | its the oxman | |
09/8/2021 01:10 | An RNS to come today from the looks of things: HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China – Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio – – Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payments, together with additional tiered royalties; HUTCHMED to receive development and commercial rights to TAZVERIK® in Greater China – – HUTCHMED to host a webcast and call on Monday, August 9, at 9:30 a.m. EDT / 2:30 p.m. BST / 9:30 p.m. HKT – see www.hutch-med.com/ev | lauders | |
02/8/2021 09:51 | Nahoon, agree US talking it’s own book hard in my opinion. China moves to regulate tech business, Bitcoin etc and it’s called everything from government manipulation to a covert strike against the western world . US moves to regulate Tech business, Bitcoin etc and it’s applauded as much over due necessity. Blatantly holds up approval of Astrazenica COVID vaccine whilst it’s own pharmas price gouge its own people and now the rest of the world and so forth. Business as usual then.. | dbadvn | |
02/8/2021 08:15 | I feel we're doing exceptionally well considering all the anti-Chinese sentiment around at the moment. | nahoon | |
01/8/2021 19:22 | explain the relevance to Hutchmed please, Thank You | nerdofsteel | |
31/7/2021 03:21 | Nice short interview here by CH: Innovative drugs are safe(r) from Chinese regulation and "interference" than generic. | lauders | |
31/7/2021 01:11 | So much for global markets! More like "So much for efficient markets!" LOL Will be nice to see HCM over 700p one of these coming days. | lauders | |
29/7/2021 20:25 | That’s a very sad sjack. Usd close at near as 41usd, hk at almost 50usd. More than 20% difference. So much for global markets! | dbadvn |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions